---
schema_version: "secwatch.filing_event.v1"
accession: "0001650664-24-000094"
form_type: "8-K"
ticker: "EDIT"
cik: "0001650664"
company_name: "Editas Medicine, Inc."
filed_at: "2024-08-07T23:59:59+00:00"
generated_at: "2026-05-31T11:47:55.249159+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Editas Medicine Q2 2024 net loss $67.6M ($0.82/share), cash $318.3M, on track for clinical data by year-end

## Summary
- Net loss $67.6M ($0.82 per share) vs $40.3M ($0.56 per share) in Q2 2023.
- Cash and equivalents $318.3M as of June 30, 2024 (down from $376.8M Q1); runway into 2026.
- R&D expenses $54.2M, up $24.4M driven by reni-cel program and in vivo research.
- On track to present additional clinical data from RUBY (SCD) and EdiTHAL (TDT) trials by year-end 2024.
- Completed enrollment of adult cohorts for both RUBY and EdiTHAL; adolescent cohort enrolled for RUBY.

## SEC filing metadata
- accession: 0001650664-24-000094
- form_type: 8-K
- ticker: EDIT
- cik: 0001650664
- company_name: Editas Medicine, Inc.
- filed_at: 2024-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650664/000165066424000094/0001650664-24-000094-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650664/000165066424000094/edit-20240807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001650664-24-000094
- JSON: https://secwatch.observer/filing/0001650664-24-000094.json
- Plain text: https://secwatch.observer/filing/0001650664-24-000094.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.